
Helomics-Patient Centric Discovery Engine



- Results on the diversity of drug response across a set of patients
- Correlations and comparisons with existing Standard-Of-Care drugs
- Model of different drug responses for patients with different tumor properties
- Results on responses to drug combinations

Helomics Clinically Validated* Functional Tumor Profile Test

Tumor Profiling assay is an LDT running in our CLIA lab.



Data from the patient's tumor testing with TruTumor™

platform)


Drug response and, biomarker profiles analyzed to generate report Report is an information "roadmap" to empower the oncologist to individualize therapy

Oncologist determines course of treatment for the patient


Data to drive featurizers

Data (TumorSpace graph db)

- 4.5M cell images from 137 tumor types
- Multiple growth metrics (AUC7, EC50, IC50, GR50, GI50)
- · Biomarker data
- · WES and WTS




Building regression models



Training a Random Forest Classifier

- Do all the extra cell imaging features help in building models?
 - 'all features'
 - · 'all features except cell count'
 - · 'only cell count'
- 'all features' and 'all features except cell count' outperformed only cell count



Summary – cell imaging ML Featurizer

- Based on multiple features
 - 431 Texture features
 - 99 Cell-Graph features
- Model based on a Random Forest Classifiers performed best at predicting response (AUC7)
- Featurization of cell images builds good models of patient tumor cell drug response
- Featurizer based on cell images can be used for our overall multi-omic approach